Clin Pharmacol Ther. 2010 Jan;87(1):27-31.

Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process.

Liberti L, Breckenridge A, Eichler HG, Peterson R, McAuslane N, Walker S.

Source

Centre for Medicines Research International Institute for Regulatory Science, London, UK. lliberti@cmr.org

Abstract

Ideally, well-designed global pharmaceutical development programs that include simultaneous submissions to multiple regulatory agencies can result in predictable regulatory approvals and expedited access to medicines for all patients. The workshops described herein investigated current trends in development and submission strategies along with regulatory review performance data in order to consider whether barriers to predictable expedited approval outcomes can be overcome through innovative clinical development approaches and a better understanding of review processes and procedures, particularly as these relate to the assessment of a product's risk-benefit profile.

PMID:: 20019699; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Congresses

MeSH Terms

Substances

Pharmaceutical Preparations

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Medicines - MedlinePlus Health Information

Supplemental Content

Related citations

Review Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry. [Alzheimer Dis Assoc Disord. 2002]
Review Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry.
Anand R. Alzheimer Dis Assoc Disord. 2002; 16 Suppl 1:S33-9.
Review Trends in development and approval times for new therapeutics in the United States. [Nat Rev Drug Discov. 2003]
Review Trends in development and approval times for new therapeutics in the United States.
Reichert JM. Nat Rev Drug Discov. 2003 Sep; 2(9):695-702.
European regulatory perspectives for innovative therapies. [Osteoporos Int. 2008]
European regulatory perspectives for innovative therapies.
Ormarsdottir S, Reginster JY, Abadie E. Osteoporos Int. 2008 Jun; 19(6):725-31.
Comparing patient access to pharmaceuticals in the UK and US. [Appl Health Econ Health Policy. 2006]
Comparing patient access to pharmaceuticals in the UK and US.
Cohen J, Cairns C, Paquette C, Faden L. Appl Health Econ Health Policy. 2006; 5(3):177-87.
Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. [Clin Pharmacol Ther. 2010]
Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
Boon WP, Moors EH, Meijer A, Schellekens H. Clin Pharmacol Ther. 2010 Dec; 88(6):848-53. Epub 2010 Oct 20.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Expediting patients' access to medicines by improving the predictability of drug...
Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process.
Clin Pharmacol Ther. 2010 Jan ;87(1):27-31.

PubMed
Effects of caffeine and glucose, alone and combined, on cognitive performance.
Effects of caffeine and glucose, alone and combined, on cognitive performance.
Hum Psychopharmacol. 2010 Jun ;25(4):310-7.

PubMed
Human host factors required for influenza virus replication.
Human host factors required for influenza virus replication.
Nature. 2010 Feb 11 ;463(7282):813-7.

PubMed
International staging system for multiple myeloma.
International staging system for multiple myeloma.
J Clin Oncol. 2005 May 20 ;23(15):3412-20. Epub 2005 Apr 4 .

PubMed
Molecular cloning of Ancient Egyptian mummy DNA.
Molecular cloning of Ancient Egyptian mummy DNA.
Nature. 1985 Apr 18-24 ;314(6012):644-5.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: